SG10201500479XA - Tumor Tissue Based Biomarkers For Bevacizumab Combination Therapies - Google Patents
Tumor Tissue Based Biomarkers For Bevacizumab Combination TherapiesInfo
- Publication number
- SG10201500479XA SG10201500479XA SG10201500479XA SG10201500479XA SG10201500479XA SG 10201500479X A SG10201500479X A SG 10201500479XA SG 10201500479X A SG10201500479X A SG 10201500479XA SG 10201500479X A SG10201500479X A SG 10201500479XA SG 10201500479X A SG10201500479X A SG 10201500479XA
- Authority
- SG
- Singapore
- Prior art keywords
- tumor tissue
- combination therapies
- tissue based
- based biomarkers
- bevacizumab combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10151109 | 2010-01-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201500479XA true SG10201500479XA (en) | 2015-03-30 |
Family
ID=43770611
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012051942A SG182520A1 (en) | 2010-01-19 | 2011-01-18 | Tumor tissue based biomarkers for bevacizumab combination therapies |
| SG10201500479XA SG10201500479XA (en) | 2010-01-19 | 2011-01-18 | Tumor Tissue Based Biomarkers For Bevacizumab Combination Therapies |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012051942A SG182520A1 (en) | 2010-01-19 | 2011-01-18 | Tumor tissue based biomarkers for bevacizumab combination therapies |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20110182892A1 (es) |
| EP (2) | EP2857040A1 (es) |
| JP (2) | JP6057718B2 (es) |
| KR (1) | KR101523419B1 (es) |
| CN (2) | CN102711830A (es) |
| AU (1) | AU2011208805A1 (es) |
| BR (1) | BR112012016229A2 (es) |
| CA (2) | CA2891047A1 (es) |
| HK (1) | HK1208804A1 (es) |
| IL (1) | IL220084A (es) |
| MX (1) | MX2012007940A (es) |
| MY (1) | MY172580A (es) |
| RU (1) | RU2605282C2 (es) |
| SG (2) | SG182520A1 (es) |
| WO (1) | WO2011089101A1 (es) |
| ZA (1) | ZA201205014B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2013001523A (es) * | 2010-08-13 | 2013-02-27 | Hoffmann La Roche | Neuroprolina como biomarcador para terapias combinadas de bevacizumab. |
| RU2659173C2 (ru) | 2012-01-13 | 2018-06-28 | Дженентек, Инк. | Биологические маркеры для идентификации пациентов для лечения антагонистами vegf |
| US9116159B2 (en) | 2012-05-22 | 2015-08-25 | Regeneron Pharmaceuticals, Inc. | VEGF-A121 assay |
| JP6666848B2 (ja) * | 2014-02-18 | 2020-03-18 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ｎｒｐ−１／ｏｂｒ複合体シグナル伝達経路により媒介される疾患の処置のための方法及び医薬組成物 |
| KR102471057B1 (ko) * | 2014-09-16 | 2022-11-28 | 리제너론 파아마슈티컬스, 인크. | 전이성 결장직장암의 항-혈관신생 치료요법에 관한 예측 및 예후 바이오마커 |
| JP2017535548A (ja) * | 2014-11-14 | 2017-11-30 | ジェネンテック， インコーポレイテッド | Ｖｅｇｆアンタゴニストの応答の予測 |
| WO2016115149A1 (en) * | 2015-01-12 | 2016-07-21 | Aveo Pharmaceuticals, Inc. | Neuropilin-1 as a serum based biomarker |
| CN104531714A (zh) * | 2015-01-23 | 2015-04-22 | 香港中文大学深圳研究院 | 适用于植物表达体系的表达贝伐单抗的基因、重组载体及产贝伐单抗植物的构建方法及应用 |
| CN105424682A (zh) * | 2015-11-17 | 2016-03-23 | 苏州浩欧博生物医药有限公司 | 一种贝伐单抗试剂盒及其抗药抗体试剂盒 |
| WO2020165483A1 (es) * | 2019-02-15 | 2020-08-20 | Universidad de Córdoba | Método de predicción de respuesta a tratamiento del cáncer con agentes antiangiogénicos |
| CN111773388B (zh) * | 2019-04-04 | 2023-07-18 | 上海奥奇医药科技有限公司 | A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用 |
| GR1009946B (el) * | 2019-06-25 | 2021-03-04 | ΕΝΟΡΑΣΙΣ ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΕΤΑΙΡΕΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ ΚΑΙ ΙΑΤΡΙΚΩΝ ΥΛΙΚΩΝ ΚΑΙ ΜΗΧΑΝΗΜΑΤΩΝ με δ.τ. "ΕΝΟΡΑΣΙΣ Α.Ε." | Οι συγκεντρωσεις της μπεβασιζουμαμπης σαν δεικτης στην ανταποκριση στη θεραπεια και στη συνολικη επιβιωση |
| RU2740361C1 (ru) * | 2020-07-31 | 2021-01-13 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) | Способ органосохраняющего лечения операбельного рака прямой кишки |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090275057A1 (en) * | 2006-03-31 | 2009-11-05 | Linke Steven P | Diagnostic markers predictive of outcomes in colorectal cancer treatment and progression and methods of use thereof |
| EP2109686A2 (en) * | 2007-01-18 | 2009-10-21 | University Of Southern California | Genetic markers for predicting responsiveness to combination therapy |
| CA2675305A1 (en) * | 2007-01-18 | 2008-07-24 | University Of Southern California | Gene polymorphisms in vegf and vegf receptor 2 as markers for cancer therapy |
-
2011
- 2011-01-18 CN CN2011800064972A patent/CN102711830A/zh active Pending
- 2011-01-18 SG SG2012051942A patent/SG182520A1/en unknown
- 2011-01-18 US US13/008,452 patent/US20110182892A1/en not_active Abandoned
- 2011-01-18 WO PCT/EP2011/050564 patent/WO2011089101A1/en active Application Filing
- 2011-01-18 MX MX2012007940A patent/MX2012007940A/es unknown
- 2011-01-18 CA CA2891047A patent/CA2891047A1/en not_active Abandoned
- 2011-01-18 BR BR112012016229A patent/BR112012016229A2/pt not_active IP Right Cessation
- 2011-01-18 SG SG10201500479XA patent/SG10201500479XA/en unknown
- 2011-01-18 MY MYPI2012700473A patent/MY172580A/en unknown
- 2011-01-18 EP EP20140193190 patent/EP2857040A1/en not_active Withdrawn
- 2011-01-18 CA CA2785774A patent/CA2785774A1/en not_active Abandoned
- 2011-01-18 EP EP11701059A patent/EP2525821A1/en not_active Withdrawn
- 2011-01-18 JP JP2012548458A patent/JP6057718B2/ja not_active Expired - Fee Related
- 2011-01-18 RU RU2012133472/15A patent/RU2605282C2/ru not_active IP Right Cessation
- 2011-01-18 AU AU2011208805A patent/AU2011208805A1/en not_active Abandoned
- 2011-01-18 KR KR1020127021418A patent/KR101523419B1/ko not_active IP Right Cessation
- 2011-01-18 CN CN201410571719.0A patent/CN104474545A/zh active Pending
-
2012
- 2012-05-31 IL IL220084A patent/IL220084A/en not_active IP Right Cessation
- 2012-07-04 ZA ZA2012/05014A patent/ZA201205014B/en unknown
-
2013
- 2013-04-03 HK HK15109509.8A patent/HK1208804A1/xx unknown
- 2013-10-04 US US14/046,913 patent/US20140099302A1/en not_active Abandoned
-
2015
- 2015-04-15 JP JP2015083506A patent/JP2015178500A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG182520A1 (en) | 2012-08-30 |
| IL220084A0 (en) | 2012-09-24 |
| JP2015178500A (ja) | 2015-10-08 |
| KR101523419B1 (ko) | 2015-05-27 |
| EP2525821A1 (en) | 2012-11-28 |
| JP6057718B2 (ja) | 2017-01-11 |
| JP2013517258A (ja) | 2013-05-16 |
| RU2605282C2 (ru) | 2016-12-20 |
| AU2011208805A1 (en) | 2012-06-21 |
| CN102711830A (zh) | 2012-10-03 |
| HK1208804A1 (en) | 2016-03-18 |
| EP2857040A1 (en) | 2015-04-08 |
| IL220084A (en) | 2016-11-30 |
| RU2012133472A (ru) | 2014-02-27 |
| US20140099302A1 (en) | 2014-04-10 |
| BR112012016229A2 (pt) | 2017-03-07 |
| KR20120123426A (ko) | 2012-11-08 |
| MX2012007940A (es) | 2012-08-03 |
| CA2891047A1 (en) | 2011-07-18 |
| US20110182892A1 (en) | 2011-07-28 |
| CN104474545A (zh) | 2015-04-01 |
| CA2785774A1 (en) | 2011-07-18 |
| ZA201205014B (en) | 2013-03-27 |
| MY172580A (en) | 2019-12-04 |
| WO2011089101A1 (en) | 2011-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL258740A (en) | Combined liposomes for cancer treatment | |
| HK1208804A1 (en) | Tumor tissue based biomarkers for bevacizumab combination therapies | |
| IL222481A0 (en) | Combination therapy | |
| EP2552323A4 (en) | COMBINATION THERAPY | |
| EP2593795A4 (en) | DIAGNOSIS IN COLORECTAL CANCER | |
| EP2542583B8 (en) | Methods for treating breast cancer | |
| GB201016139D0 (en) | Cancer phosholipidome | |
| GB2496805B (en) | Compounds for photodynamic therapy | |
| EP2748608A4 (en) | LUNG CANCER TESTS | |
| EP2635286A4 (en) | METHOD FOR THE TREATMENT OF CANCER | |
| EP2524702A4 (en) | DIAGNOSTIC TO CANCER | |
| IL222958A0 (en) | Cancer treatment | |
| GB201012590D0 (en) | Methods for diagnosing cancer | |
| HRP20181757T1 (hr) | Kombinirana terapija za liječenje raka dojke | |
| HK1179145A1 (en) | Medical stapler | |
| EP2715354A4 (en) | CLEAR MARKING DURING A CANCER SURGERY | |
| GB201005394D0 (en) | Therapy | |
| GB201106630D0 (en) | Cancer therapy | |
| EP2629766A4 (en) | COMBINATION THERAPY | |
| GB201019034D0 (en) | Treatment for tumors | |
| GB201020513D0 (en) | Cancer therapy | |
| HK1169926A1 (en) | Healthy shoe | |
| ZA201208905B (en) | Cancer therapy method | |
| GB201118220D0 (en) | Cancer therapy | |
| GB201014042D0 (en) | Clinical radiotherapy apparatus |